Abbott’s Gallant ICD and CRT-D Devices Receives the US FDA’s Approval for Heart Rhythm Disorder with Bluetooth Connectivity

 Abbott’s Gallant ICD and CRT-D Devices Receives the US FDA’s Approval for Heart Rhythm Disorder with Bluetooth Connectivity

Abbott Collaborates with Omada Health to Provide Integrated Digital Health and Coaching Experience for Patients with Type 2 Diabetes

Shots:

  • Abbott’s Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) are developed for heart rhythm disorders including patient-preferred design without compromising battery longevity and MRI compatibility also allows Bluetooth connectivity on the smartphones for improved remote monitoring, increased patient/physician engagement and streamlined communications
  • The Gallant pairs with Abbott’s secure myMerlinPulse for streamline communication between doctors and their patients suitable for both iOS and Android. Additionally, it allows to access data device performance, transmission history and helps in continues monitoring for asymptomatic episodes leading to early intervention
  • Abbott’s Gallant has also received the CE Mark which offers treatment plans and the increased facilities for the patient leading to better outcomes

Click here to read full press release/ article | Ref: Abbott | Image: PharmaWorld

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post